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Abstract
AIM: To make orthotopic colon cancer murine models 
a more clearly understood subject. The orthotopic 
tumor models have been found to be more relevant 
in replicating the human disease process as compared 
to heterotopic models, many techniques for making 
orthotopic colorectal murine models have been 
reported.
METHODS: We evaluated the current literature for 
various reported orthotopic colon cancer models 
to understand their techniques, advantages and 
limitations. An extensive literature review was 
performed by searching the National Library of Medicine 
Database (PubMed) using MeSH terms animal model; 
colon cancer; orthotopic model; murine model. Twenty 
studies related to colon cancer orthotopic xenograft 
model were evaluated in detail and discussed here. 
RESULTS: The detailed analysis of all relevant reports 
on orthotopic model showed tumor take rate between 
42%-100%. While models using the enema technique 
and minimally invasive technique have reported 
development of tumor from mucosa with tumor take 
rate between 87%-100% with metastasis in 76%-90%.
CONCLUSION: Over the years, the increased under-
standing of the murine models of human colon cancer 
has resulted in the development of various models. 
Each reported model has some limitations. These latest 
models have opened up new doors for continuing 
cancer research for not only understanding the colon 
cancer pathogenesis but also aid in the development 
of newer chemotherapeutic drugs as they mimic the 
human disease closely.
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Core tip:  The murine models of colon cancer 
represent an important tool for understanding the 
etiopathogenesis and evaluating management 
strategies for colorectal cancer, thus representing a 
resource of immense potential in cancer research. 
Over the years, the increased understanding of the 
murine models of human colon cancer have resulted in 
the development of various models. We evaluated the 
current literature for various reported orthotopic colon 
cancer models. Our paper discusses the techniques, 
results, advantages and limitations of the presently 
available murine models of colorectal cancer so that a 
researcher can choose an appropriate colorectal cancer 
murine model which fits their research goals.
Mittal VK, Bhullar JS, Jayant K. Animal models of human 
colorectal cancer: Current status, uses and limitations. World J 
Gastroenterol 2015; 21(41): 11854-11861  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v21/i41/11854.htm  DOI: 
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INTRODUCTION
National Cancer Institute and SEER (Surveillance, 
Epidemiology and End Result) Program 2011, reported 
the incidence of colon cancer as 43.3 and the number 
of people dying from colon cancer as 15.9 per 100000 
men and women per year. Colon cancer remains the 
third most common cancer among men as well as 
women and 2nd leading cause of cancer related deaths 
in United States[1]. 
Recently, there have been many advances in 
the understanding of colon cancer epidemiology, 
pathogenesis, pathology, chemoprevention and 
therapeutic options, which seem to have emanated 
from continuing basic and clinical research. Host 
genetic factors play a critical role in the patho­
physiology of most human cancers. The immense 
biological complexity of colon cancer has kindled the 
development of more apt research design that could 
simulate in a natural and spontaneous fashion the 
pathophysiologic features of cancer biology. Rodent 
models have many desired attributes and they share 
a wide variety of characteristics with human that 
has proven to be important in comprehending many 
complex molecular facets of colon cancer[2]. They also 
act as an invaluable tool in the development of newer 
chemotherapeutic drugs. This has made the laboratory 
mouse (Mus musculus) as one of the most attractive 
entity in oncologic research[3,4]. 
Thus there is a constant endeavor to develop 
an animal model that closely mimics the malignant 
disease process of humans. Although many animal 
models were tried but as per NCI data only two animal 
models based on breast and colon cancer histology are 
successfully used in preclinical trials[5,6]. Together with 
that further studies have displayed that the human 
xenograft models have shown better results than the 
murine allograft models in drug development. Till date 
more than 100000 rodents have been sacrificed for the 
development of chemotherapeutic drugs. Along with 
that, this fact also remains that, millions of people all 
over the world are alive today because of the animal 
research[7­9].
Colorectal cancer basic research has grown itself on 
the animal models, which have now become the pillars 
for understanding the pathogenesis and for developing 
newer chemotherapeutic drugs. The murine models 
depict a resource of immense potential, as an intricate 
disorder like colon cancer can be simultaneously 
witnessed and manipulated by the researchers. Our 
knowledge in this field has evolved a lot, and many 
mouse models have been reported, but each has 
certain limitations as there is no spontaneous colon 
cancer and a carcinogen is required for tumor induction 
in the rodents. Also, many of the mouse models have 
inter­animal variability in the development of tumors 
in the intestine. In spite of that animal models have 
become an important tool in better understanding 
the effect of genetic alterations on the disease 
process[10­12]. 
We reviewed the literature for evaluating the 
different techniques of developing orthotopic xenograft 
murine colorectal cancer models, their advantages and 
limitations. This was done to offer the investigators 
an appropriate model for research in order to 
obtain robust and translatable data to aid further 
understanding of colorectal cancer.
MATERIALS AND METHODS
An extensive review of the literature on murine models 
of colon carcinogenesis was performed by searching 
the National Library of Medicine Database (PubMed) 
on 12/28/2014. The MEDLINE search was made using 
MeSH terms: animal model; chemoprevention; colon­
carcinogenesis; min­mice; colon cancer; colorectal 
cancer; xenograft, heterotopic model, orthotopic 
model, murine model. We found a total of 5622 
literatures by searching above key words. All the 477 
relevant articles were analyzed and interpreted in 
detail and of these 20 manuscripts pertaining to colon 
cancer orthotopic xenograft model were included in 
this review. 
RESULTS
Based on detailed analysis of all relevant reports on 
orthotopic colorectal cancer xenograft model, we 
categorized them into different groups according to 
the techniques used to create these models. The 
outcomes using different techniques in various studies 
are discussed in Table 1.
Open surgical technique
Ogata et al[13] in 1998, used in vivo KM12 SM cell lines 
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and injected them into cecal wall of nude mice through 
an open surgical technique for making the orthotopic 
xenograft model. They reported tumor take rate of 
100% and metastasis to the regional mesenteric 
lymph nodes in 25% and to liver in 50%. 
Hackl et al[14] in 2012, injected human colon can­
cer cell lines HT 29 and HCT 116 transfected with 
human chorionic gonadotropin (b­hCG) and luciferase, 
orthotopically into the caecal wall of severe combined 
immunodeficient (SCID) mice. The developing tumor 
produces b­hCG and luminescent protein luciferin. The 
levels of these markers correlate with tumor burden, 
completeness of resection and recurrence. They 
reported tumour take rates between 87% to 100%, 
metastases to lymph nodes and liver in 50% and lungs 
in 25% following intracaecal cell injection.
Priolli et al[15] in 2012, also used the open surgical 
method for colonic diversion with distal fistula for­
mation. This was followed by injecting of WiDR 
colorectal (CCL­218) adenocarcinoma cell line into the 
submucosa of the fistula made in the mice. Tumor 
growth was reported in 42.8% mice with metastasis in 
none.
Enema technique model
Takahashi et al[16] in 2004, developed a technique by 
inducing short term colitis in nude mice by an irritant 
agent, 3% dextran sulfate sodium (DSS) followed 
by instillation of human colon cancer cells LS174T 
transanally. They reported a tumor take rate of 95% in 
rectum after 2 wk but could not observe any significant 
metastasis.
Kishimoto et al[17] in 2013, used 4% acetic acid 
solution for two minutes, followed by flushing with 6 
ml phosphate buffered saline (PBS) in order to disrupt 
the epithelial cell layer of the distal rectal mucosa 
followed by mouse colorectal cancer cell line CT­26 
and the human colorectal cancer cell line HCT­116 
cells, expressing green fluorescent protein (GFP) 
were instilled transanally. Authors noted rectal tumor 
development in 100% of the mice. Spontaneous lymph 
node metastasis and lung metastasis were found in 
over 90% of mice.
Microinjection technique
Donigan et al[18] in 2009, used an optical microscope, 
to inject murine colon cancer (CT­26) cells into the 
rectal wall of the nude mice under magnification 
(10­100 ×) with an overall tumor take rate of 65% 
and distant metastasis in 3.3%.
Using a similar technique, Zigmond et al[19] in 2011 
reported a murine model in which the murine and 
human colon cancer tumor cells ­ C57BL/6 CRC tumor 
cells and SW620, SW480 and LS174T respectively 
were injected into the wall of distal rectum through 
a murine colonoscope (Coloview­ Karl Storz). They 
reported tumor take rate of 95% with no metastasis.
Transanal low dose electrocoagulation technique
Bhullar et al[20] in 2010, transanally instilled human (LS­
174T and HT­29) and murine (CRL­2638 and CRL­2639) 
colon cancer cell lines in SCID and nude mice, after 
transanal low dose mucosal electrocoagulation of the 
colon. Overall tumors developed in 87.5% of mice 
(42/48) i.e., 12 of 12 and 11 of 12 mice with murine 
tumor lines (CRL­2638 and CRL­2639, respectively) 
and in 7 of 12 and 12 of 12 mice with human tumor 
lines (HT­29 and LS­174T, respectively). While overall 
lymph nodal and distant metastasis was found in 
66.66% cases (32/48) i.e., 12 of 12 and 6 of 12 mice 
with murine tumor lines (CRL­2638 and CRL­2639, 
respectively) and in 10 of 12 and 4 of 12 mice with 
human tumor lines (HT­29 and LS­174T, respectively).
DISCUSSION
After reviewing all the current literature related to 
orthotopic xenograft murine colorectal cancer models 
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Table 1  Characteristics of reported orthotopic murine models of human colon cancer
Technique Author Year Mice type Cell-line used Tumor development 
(%)/origin
Lymph node 
metastasis (%)
Distant 
metastasis (%)
Open surgical Ogata 1998 Nude Human colon carcinoma KM12 SM cells 100/Mural 25   10 (Lung)
  50 (Liver)
Hackl 2012    Nude Human colon cancer cells, transfected with 
hCG and luciferase 
87.5-100/Mural 50   25 (Lung)
  50 (Liver)
Priolli 2012  Nude Colorectal adenocarcinoma cell line 
(CCL-218) 
42.8/Mural 00 00
Enema model Takahashi 2004  Nude Human colon cancer cells, LS174T 95/Mucosal NS NS
Kishimoto 2013  Nude Mouse rectal cancer cells, expressing green 
fluorescent protein (GFP) 
100/Mucosal 90 90 (Lung)
09 (Liver)
Microinjection Donigan 2009 Nude Murine colon cancer (CT26) cells 65/Mural NA 3.3
Zigmond 2011 Nude Murine colon cancer C57BL/6 CRC cells 95/Mural NA NA
Human colon cancer cells SW620, SW480 
and LS174T
Transanal low dose   
electrocoagulation 
Bhullar 2010 Nude/
SCID
Murine cell line CRL-2639, CRL-2638 92-100/Mucosal 50-100 41-50
Human cell line HT-29,
LS-174T
58-100/Mucosal 33-83 0-83.33
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variations to study colorectal tumorigenesis in animal 
models. Pocard et al[26] in 1996 made subcutaneous 
xenografts by injection of cancer cells subcutaneously 
in flanks of the mice. When the tumors acquired a size 
of > 1 cm3, the mice were euthanized and the tumor 
sliced into pieces measuring 2 mm × 2 mm × 2 mm. 
These sections were later implanted under anesthesia 
through a midline abdominal incision to the serosal 
surface of cecum and fixed with a stitch and abdomen 
closed. Identically, in another model, the tumor cells 
were injected into colonic submucosa from the cecal 
serosa rather than fixing with a stitch..
Ogata et al[13] in 1998, followed the similar tech­
nique for orthotopic inoculation of human colonic 
cancer cell lines KM12 SM into the cecal wall of nude 
mice. They found tumors growing in 100% mice and 
metastasis to the regional mesenteric lymph nodes in 
25% and to liver in 50%[27­29].
The open orthotopic models have multiple down­
sides. The initial immune response following the 
open and minimally invasive colon resections checks 
its authenticity. They do not cause mesenteric and 
retroperitoneal lymphatic metastases. Furthermore, 
the prior proliferation necessary in these models alters 
the growth and dissemination potential of the cell 
lines[30­33]. 
In 2012, Hackl et al[14] presented only study of 
its kind which thoroughly compares all three ways of 
human xenograft models of CRC i.e., subcutaneous, 
orthotopic and intrasplenic. In this review we have 
discussed the technical aspects of only orthotopic 
xenograft done by open method. This new technique 
to execute xenografts from human colon cancer cell 
lines, transfected with luciferase and beta­hCG. In 
the Orthotopic model, open surgical technique was 
used. Cecum was assessed through midline incision 
following which trypan blue was injected into cecal 
wall. The cecum was then being stabilized carefully 
on a scalpel holder to prevent spillage of tumor cells. 
Using a 10 mL Hamilton syringe and 30G needle 5 ml 
cells (5 × 105) were infused into the cecal wall under 
4 × magnification. Though this approach has a high 
tumor take rate of 87.5%­100% but the pitfall is 
that it is an intricated technique requiring specialized 
training, expertise hands and suitable instruments. 
Intrasplenic tumor cell injection was followed by a 
speedy colonization of the cancer cells to liver and 
lungs, within a day, which could not be explained by 
spontaneous metastasis. Mice yield to considerable 
tumor load within a few weeks and drug efficacy also 
could not be studied.
Priolli et al[15] in 2012 designed another open 
surgical method in which colon diversion and distal 
fistula formed, cancer cells were infused in the 
submucosa of the fistula. Scintigraphy with 99mTc­
MIBI was performed to identify the tumor and monitor 
its growth. Tumors developed spontaneously in the 
in detail, it is clear that there has been enormous 
development in the murine models over time. The 
latest models are more applicative with high tumor 
take rates, but still they have some limitations.
The historical murine cancer models were xenograft 
heterotopic models which laid the foundation for the 
development of newer orthotopic models. These 
xenograft heterotopic models were traditionally made 
by subcutaneous implantation of human colon cancer 
cells into either, nude T­cell deficient mice or NOD 
SCID mice (non­obese diabetic/severe combined 
immunodeficiency). The formed tumor is located 
externally in this model, so, its growth can be easily 
and accurately monitored (Figure 1). 
Though making a heterotopic model is easy, but 
it has multiple pitfalls. It does not mimic the human 
disease process because of the extra ­ anatomical 
location of the tumor and the absence of metastasis 
from the subcutaneous location made the model 
inappropriate for study of the spontaneous metastatic 
process. In the present scenario, the only role of the 
heterotopic model is its use in making the orthotopic 
model. Subcutaneously grown tumor is resected 
after euthanizing the animal and small parts of the 
tumor are then embedded on the colon to make the 
orthotopic model[21,22]. The technically more advanced 
orthotopic xenograft murine models are formed by 
implanting colorectal cancer cells into colon and they 
are superior to the traditional subcutaneous xenograft 
tumor models. The orthotopic model resembles the 
entire spectrum of colorectal cancer ranging from in 
situ tumor to metastatic tumor. Commercially available 
cell lines can be used for making the orthotopic 
tumors, but these cell lines are altered by years of 
cultures in vitro, so injecting cells directly from tumors 
is preferred[23­25].
As discussed earlier, there are various techniques 
for instilling cancer cells into colon or rectum of murine 
animal models.
To begin with, investigators have used open 
surgery methods of implanting tumor cells with many 
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Figure 1  Showing a heterotropic colonic tumor on the flank of the mouse. 
(Image used from author’s personal collection).
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submucosa and histological examination revealed 
poorly differentiated tumor cells identically to the cells 
implanted. Distal fistula allowed easy monitoring of 
the tumor growth and assessing the effect of cytotoxic 
therapy. Tumor metastasis was not seen which may be 
due to insufficient time for tumor spread, insufficient 
number of cells inoculated or genotypic variance of 
tumor cells regarding invasiveness and metastatic 
potential.
Next is the enema model technique which requires 
induction of colitis followed by instillation of cancer 
cells transanally. Takahashi and associates in 2004 
used a distinct non­surgical technique of orthotopic 
implantation. They infused 3% dextran sulfate sodium 
(DSS) to induce colitis followed by which cancer 
cells were instilled transanally. Clapper et al[34] also 
analyzed this approach by cyclically administering DSS, 
which generated colorectal dysplasia and carcinoma 
with similar pathological characteristics as humans. 
The frequency and profusion of these lesions differ, 
depending on the genre of mouse used, dose and 
schedule of DSS. Also the advancement of these tumors 
to invasive cancer could be potentiated by delivering 
DSS simultaneously with a known colon carcinogen 
{azoxymethane (AOM), 2­ amino­3­methylimidazo[4,5­
fl] quinoline (IQ), 2­amino­1­methyl­6­phenylimidazo 
[4,5­b] pyridine (PhIP)} or iron[16]. 
Kishimoto et al[17] in 2013 also used similar 
technique for orthotopic implantation of mouse rectal 
cancer cells, stably expressing green fluorescent 
protein (GFP). Instilling acetic acid solution dis­
integrated the epithelial cell layer of the rectal 
mucosa. CT26­GFP cells in Matrigel were injected in 
rectal mucosa 4mm from rectal ring. The anus was 
promptly sealed by tape to restrain cell leakage. The 
inoculated tumor cells were noninvasively observed 
by fluorescence microscope. The mice were then 
euthanized for histological studies and to investigate 
potential metastasis. The carcinoma developed in 
100% of mice, it initiated in rectal mucosa and then 
invaded submucosa. The tumor metastasized to the 
lymph nodes and lungs in 90% while dissemination to 
the liver was seen in only 9% of mice, contrary to the 
fact that liver is the most common site for metastasis 
of colorectal carcinoma. The authors elucidated it by 
the development of tumor in the lower rectum, which 
primarily drains in systemic venous circulation. As 
tumors arise only in rectum, which may not be useful 
in colonic studies, is major limitation of this model.
Another developed modality was microinjection 
technique which involves instillation of tumor cells 
directly into the colonic wall by microinjection. Donigan 
et al[18] in 2009 has devised this non­operative 
technique by using optical microscope in which the 
colon cancer cells were injected into the rectal wall of 
the mouse under magnification (10­100 ×) with an 
overall uptake rate of 65%. But the hitch was that 
the injection of the cells into the rectal wall evolved in 
cancers not emanating from the mucosa. Using the 
identical notion, Zigmond et al[19] in 2011 reported a 
murine model in which the tumor cells were injected 
into the wall of colon through a murine colonoscope 
(Coloview­Karl Storz). They reported tumor take rate 
of 95% with no metastasis. But, by the use of coloview 
the tumor cells can be implantated only in distal 
rectum[35,36]. 
For overcoming problems and deficiencies with 
the previously described colorectal cancer murine 
models, Bhullar et al[20] 2010 came up with a very 
impressive noninvasive technique i.e., transanal low 
dose electrocoagulation technique. They reported 
a true orthotopic murine model using tumor cell 
implantation after low­dose colonic mucosal coagulation 
through a small transanal electrode resulting in 
limited mucosal injury. Subsequently, they instilled 
the tumor cells transanally on the injured mucosa, 
which then proliferated in the non­ischemic bed. The 
resultant tumors grew from the mucosal surface and 
subsequently involved the deeper colonic layers. The 
colonoscopic (coloview) view of the normal mouse colon 
shows a smooth circumferential mucosa, while the 
orthotopically grown tumor from the mucosal surface 
can be easily detected and followed up (Figure 2).
Tumors developed in 87.5% of the mice (42/48) 
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Figure 2  Colonoscopic picture on the left show a normal murine colon with smooth circumferential mucosa. While the colonoscopic picture on the right 
shows the orthotopic tumor growth (marked). (Image used from author’s personal collection).
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i.e., 12 of 12 and 11 of 12 mice with murine tumor lines 
(CRL­2638 and CRL 2639, respectively) and in 7 of 12 
and 12 of 12 mice with human tumor lines (HT­29 and 
LS 174T, respectively). The tumors were initially smaller, 
but over time grew bigger to invade the surrounding 
structures like the bladder, pelvic bones, etc. (Figure 3). 
Histologic evaluation revealed that these tumors grew 
from the mucosal lining (Figure 4). Overall Metastatic 
disease i.e., lymph nodal in 32/48 i.e., 66.66%, while 
liver, omentum and peritoneum involvement was 
seen in 43.75% (21/48) of cases. Orthotopic model 
using HT­29, LS 174T human cell lines showed tumor 
development in 58%­100% cases, lymph node and 
liver metastasis seen in 33­83.33% cases[20]. 
This noninvasive model has succeeded in dealing 
with most of the limitations of the antecedent mo­
dels as: (1) there is no need of laparotomy for tumor 
implantation at colon or rectum; (2) easy to learn 
noninvasive technique with high reproducibility; (3) 
it closely mimics the natural development of disease 
process in humans; and (4) tumor uptake was 100% 
and metastasis was 83.33% with human cell line (LS 
174T).
This model has come as a boon in the research for 
human colon cancer. It has enormous potentials and 
can be used to study tumor development, metastasis, 
and evaluation of novel chemotherapeutics for the 
colorectal cancer.
With the escalating worldliness of modelling 
carcinogenesis in mice, an intricate disorder can 
be simultaneously witnessed and manipulated by 
the researchers. The recently developed orthotopic 
xenograft murine models of colon carcinoma have 
added a new dimension in the research of colorectal 
cancer by overcoming limitations of the earlier ones. 
The model by our group has overcome most of 
the shortcomings of the antecedent models and has 
opened new way for understanding disease process 
and testing therapeutic drugs that can potentially 
benefit patients of human colorectal cancer. 
At the same time better understanding of the 
disease process along with the improved technology 
available to the future researchers, we can expect 
more advancement in these orthotopic murine models.
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